Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 1265 entries
Sorted by: Best Match Show Resources per page
How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?

interventions

[No authors listed]
GSID: iF9K0fm75ZQJ
GW Comstock - The International Journal of Tuberculosis and …, 1999 - ingentaconnect.com

Recommendations regarding how long isoniazid should be taken to prevent tuberculosis have gradually shifted from 12 to 6 months of treatment. These recommendations and the …

Royal College of Physicians

college

[No authors listed]
GSID: hpJixhKfzlMJ
AM Barnes, PH de Jonge, S Varney, B Fairclough… - Thorax, 2004 - ncbi.nlm.nih.gov

Fitzgerald DW, Severe P, Joseph P, Mellon LR, Noel E, Johnson WD, Jr, Pape JW. No effect of isoniazid prophylaxis for purified protein derivative-negative HIV-infected adults living in a …

Cite
Barnes, A. M., de Jonge, P. V. H., Varney, S., Fairclough, B., & Sullivan, T. (2004). Royal College of Physicians. Thorax, 59, 1-232.
Barnes, Alisa Mayes, et al. "Royal College of Physicians." Thorax 59 (2004): 1-232.
Copy Download .nbib Format: MLA
[A case of rib tuberculosis and chest wall abscess with multi-drug hypersensitivity reactions].

Mikrobiyoloji bulteni

Akduman Alaşehir E, Sarıman N, Yaman G, Olgaç M, Saygı A.
PMID: 26313287
Mikrobiyol Bul. 2015 Jul;49(3):454-60.

Extrapulmonary tuberculosis is the reactivation of the remaining latent organism which spreads during primary infection by the lymphohematogenous way. It should be considered in the differential diagnosis especially in endemic countries for tuberculosis. Tuberculosis (TB) treatment is based on...

Cite
Akduman Alaşehir E, Sarıman N, Yaman G, et al. Çok ilaca aşırı duyarlılık reaksiyonu görülen bir kot tüberkülozu ve göğüs duvarı apsesi olgusu. [A case of rib tuberculosis and chest wall abscess with multi-drug hypersensitivity reactions]. Mikrobiyol Bul. 2015;49(3):454-60
Akduman Alaşehir, E., Sarıman, N., Yaman, G., Olgaç, M., & Saygı, A. (2015). Çok ilaca aşırı duyarlılık reaksiyonu görülen bir kot tüberkülozu ve göğüs duvarı apsesi olgusu. [A case of rib tuberculosis and chest wall abscess with multi-drug hypersensitivity reactions]. Mikrobiyoloji bulteni, 49(3), 454-60.
Akduman Alaşehir, Elçin, et al. "Çok ilaca aşırı duyarlılık reaksiyonu görülen bir kot tüberkülozu ve göğüs duvarı apsesi olgusu." [A case of rib tuberculosis and chest wall abscess with multi-drug hypersensitivity reactions]. Mikrobiyoloji bulteni vol. 49,3 (2015): 454-60.
Akduman Alaşehir E, Sarıman N, Yaman G, Olgaç M, Saygı A. Çok ilaca aşırı duyarlılık reaksiyonu görülen bir kot tüberkülozu ve göğüs duvarı apsesi olgusu. [A case of rib tuberculosis and chest wall abscess with multi-drug hypersensitivity reactions]. Mikrobiyol Bul. 2015 Jul;49(3):454-60. Turkish. PMID: 26313287.
Copy Download .nbib Format: NLM
Integration of TB-HIV services at an ANC facility in Frances Baard District, Northern Cape, South Africa.

Public health action

Peters JA, Heunis C, Kigozi G, Osoba T, van der Walt M.
PMID: 26400599
Public Health Action. 2015 Mar 21;5(1):30-5. doi: 10.5588/pha.14.0033.

BACKGROUND: Integrated tuberculosis-human immunodeficiency virus (TB-HIV) service delivery as part of maternal health services, including antenatal care (ANC), is widely recommended. This study assessed the implementation of collaborative TB-HIV service delivery at a hospital-based ANC service unit.METHODS: A record...

Cite
Peters JA, Heunis C, Kigozi G, et al. Integration of TB-HIV services at an ANC facility in Frances Baard District, Northern Cape, South Africa. Public Health Action. 2015;5(1):30-5doi: 10.5588/pha.14.0033.
Peters, J. A., Heunis, C., Kigozi, G., Osoba, T., & van der Walt, M. (2015). Integration of TB-HIV services at an ANC facility in Frances Baard District, Northern Cape, South Africa. Public health action, 5(1), 30-5. https://doi.org/10.5588/pha.14.0033
Peters, J A, et al. "Integration of TB-HIV services at an ANC facility in Frances Baard District, Northern Cape, South Africa." Public health action vol. 5,1 (2015): 30-5. doi: https://doi.org/10.5588/pha.14.0033
Peters JA, Heunis C, Kigozi G, Osoba T, van der Walt M. Integration of TB-HIV services at an ANC facility in Frances Baard District, Northern Cape, South Africa. Public Health Action. 2015 Mar 21;5(1):30-5. doi: 10.5588/pha.14.0033. PMID: 26400599; PMCID: PMC4525359.
Copy Download .nbib Format: NLM
Tuberculosis of Acromioclavicular Joint.

Journal of clinical and diagnostic research : JCDR

Agarwal A, Bhandari A, Maheshwari R.
PMID: 28511468
J Clin Diagn Res. 2017 Mar;11(3):RD03-RD04. doi: 10.7860/JCDR/2017/23186.9588. Epub 2017 Mar 01.

Tuberculosis (TB) arthritis accounts for approximately 1%-3% of all cases of TB and for approximately 10%-11% of extra pulmonary cases. Isolated acromioclavicular joint TB has been reported rarely with varied presentations as case series of one to three cases...

Cite
Agarwal A, Bhandari A, Maheshwari R. Tuberculosis of Acromioclavicular Joint. J Clin Diagn Res. 2017;11(3):RD03-RD04doi: 10.7860/JCDR/2017/23186.9588.
Agarwal, A., Bhandari, A., & Maheshwari, R. (2017). Tuberculosis of Acromioclavicular Joint. Journal of clinical and diagnostic research : JCDR, 11(3), RD03-RD04. https://doi.org/10.7860/JCDR/2017/23186.9588
Agarwal, Archit, et al. "Tuberculosis of Acromioclavicular Joint." Journal of clinical and diagnostic research : JCDR vol. 11,3 (2017): RD03-RD04. doi: https://doi.org/10.7860/JCDR/2017/23186.9588
Agarwal A, Bhandari A, Maheshwari R. Tuberculosis of Acromioclavicular Joint. J Clin Diagn Res. 2017 Mar;11(3):RD03-RD04. doi: 10.7860/JCDR/2017/23186.9588. Epub 2017 Mar 01. PMID: 28511468; PMCID: PMC5427394.
Copy Download .nbib Format: NLM
Hepatotoxicity in Children Receiving Isoniazid Therapy for Latent Tuberculosis Infection.

Journal of the Pediatric Infectious Diseases Society

Chang SH, Nahid P, Eitzman SR.
PMID: 26625385
J Pediatric Infect Dis Soc. 2014 Sep;3(3):221-7. doi: 10.1093/jpids/pit089. Epub 2014 Jan 15.

BACKGROUND: The frequency of isoniazid hepatotoxicity is low in children receiving isoniazid therapy for latent tuberculosis infection. However, isoniazid hepatotoxicity may cause liver failure and death. We evaluated children who developed isoniazid hepatotoxicity to determine demographic and clinical characteristics.METHODS:...

Cite
Chang SH, Nahid P, Eitzman SR. Hepatotoxicity in Children Receiving Isoniazid Therapy for Latent Tuberculosis Infection. J Pediatric Infect Dis Soc. 2014;3(3):221-7doi: 10.1093/jpids/pit089.
Chang, S. H., Nahid, P., & Eitzman, S. R. (2014). Hepatotoxicity in Children Receiving Isoniazid Therapy for Latent Tuberculosis Infection. Journal of the Pediatric Infectious Diseases Society, 3(3), 221-7. https://doi.org/10.1093/jpids/pit089
Chang, Shiow-Huey, et al. "Hepatotoxicity in Children Receiving Isoniazid Therapy for Latent Tuberculosis Infection." Journal of the Pediatric Infectious Diseases Society vol. 3,3 (2014): 221-7. doi: https://doi.org/10.1093/jpids/pit089
Chang SH, Nahid P, Eitzman SR. Hepatotoxicity in Children Receiving Isoniazid Therapy for Latent Tuberculosis Infection. J Pediatric Infect Dis Soc. 2014 Sep;3(3):221-7. doi: 10.1093/jpids/pit089. Epub 2014 Jan 15. PMID: 26625385.
Copy Download .nbib Format: NLM
Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?.

Therapeutic advances in chronic disease

Field SK.
PMID: 26137207
Ther Adv Chronic Dis. 2015 Jul;6(4):170-84. doi: 10.1177/2040622315582325.

Acquired drug resistance by Mycobacterium tuberculosis (MTB) may result in treatment failure and death. Bedaquiline was recently approved for the treatment of multidrug-resistant tuberculosis (MDR-TB). This report examines the available data on this novel drug for the treatment of...

Cite
Field SK. Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?. Ther Adv Chronic Dis. 2015;6(4):170-84doi: 10.1177/2040622315582325.
Field, S. K. (2015). Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?. Therapeutic advances in chronic disease, 6(4), 170-84. https://doi.org/10.1177/2040622315582325
Field, Stephen K. "Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?." Therapeutic advances in chronic disease vol. 6,4 (2015): 170-84. doi: https://doi.org/10.1177/2040622315582325
Field SK. Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?. Ther Adv Chronic Dis. 2015 Jul;6(4):170-84. doi: 10.1177/2040622315582325. PMID: 26137207; PMCID: PMC4480545.
Copy Download .nbib Format: NLM
Personalized information system for the control of tuberculosis in resource-limited settings: A simplistic proposal approach.

International journal of mycobacteriology

Thumamo Pokam BD, Guemdjom PW.
PMID: 28043609
Int J Mycobacteriol. 2016 Dec;5:S54. doi: 10.1016/j.ijmyco.2016.09.047. Epub 2016 Nov 12.

Passive case finding remains the mainstay of tuberculosis (TB) control in several resource-limited countries. Although TB prevalence and mortality rates have declined in recent years, an estimated 3 million cases a year still go undetected and/or unreported, and delays...

Cite
Thumamo Pokam BD, Guemdjom PW. Personalized information system for the control of tuberculosis in resource-limited settings: A simplistic proposal approach. Int J Mycobacteriol. 2016;5:S54doi: 10.1016/j.ijmyco.2016.09.047.
Thumamo Pokam, B. D., & Guemdjom, P. W. (2016). Personalized information system for the control of tuberculosis in resource-limited settings: A simplistic proposal approach. International journal of mycobacteriology, 5S54. https://doi.org/10.1016/j.ijmyco.2016.09.047
Thumamo Pokam, Benjamin D, and Guemdjom, Prisca W. "Personalized information system for the control of tuberculosis in resource-limited settings: A simplistic proposal approach." International journal of mycobacteriology vol. 5 (2016): S54. doi: https://doi.org/10.1016/j.ijmyco.2016.09.047
Thumamo Pokam BD, Guemdjom PW. Personalized information system for the control of tuberculosis in resource-limited settings: A simplistic proposal approach. Int J Mycobacteriol. 2016 Dec;5:S54. doi: 10.1016/j.ijmyco.2016.09.047. Epub 2016 Nov 12. PMID: 28043609.
Copy Download .nbib Format: NLM
Drug resistance pattern of Mycobacterium tuberculosis in the province with highest incidence of tuberculosis in Iran.

International journal of mycobacteriology

Mansoori N, Douraghi M, Vaziri F, Rajabloo AA, Sheikhi M, Taziki M, Atarjalali M.
PMID: 28043506
Int J Mycobacteriol. 2016 Dec;5:S131. doi: 10.1016/j.ijmyco.2016.09.014. Epub 2016 Oct 22.

OBJECTIVE/BACKGROUND: Incidence of tuberculosis (TB) in Golestan Province is consistently higher than other provinces of Iran. This study aimed to determine the rate of drug resistance to first-line antibiotics in Mycobacterium tuberculosis (MTB) isolates recovered from new cases in...

Cite
Mansoori N, Douraghi M, Vaziri F, et al. Drug resistance pattern of Mycobacterium tuberculosis in the province with highest incidence of tuberculosis in Iran. Int J Mycobacteriol. 2016;5:S131doi: 10.1016/j.ijmyco.2016.09.014.
Mansoori, N., Douraghi, M., Vaziri, F., Rajabloo, A. A., Sheikhi, M., Taziki, M., & Atarjalali, M. (2016). Drug resistance pattern of Mycobacterium tuberculosis in the province with highest incidence of tuberculosis in Iran. International journal of mycobacteriology, 5S131. https://doi.org/10.1016/j.ijmyco.2016.09.014
Mansoori, N, et al. "Drug resistance pattern of Mycobacterium tuberculosis in the province with highest incidence of tuberculosis in Iran." International journal of mycobacteriology vol. 5 (2016): S131. doi: https://doi.org/10.1016/j.ijmyco.2016.09.014
Mansoori N, Douraghi M, Vaziri F, Rajabloo AA, Sheikhi M, Taziki M, Atarjalali M. Drug resistance pattern of Mycobacterium tuberculosis in the province with highest incidence of tuberculosis in Iran. Int J Mycobacteriol. 2016 Dec;5:S131. doi: 10.1016/j.ijmyco.2016.09.014. Epub 2016 Oct 22. PMID: 28043506.
Copy Download .nbib Format: NLM
The majority of patients with multidrug-resistant tuberculosis in Sub-Saharan Africa present a concomitant resistance to pyrazinamide.

International journal of mycobacteriology

Daneau G, Gumusboga M, De Rijk P, Trebucq A, Rigouts L, Van Deun A, de Jong BC.
PMID: 28043604
Int J Mycobacteriol. 2016 Dec;5:S46-S47. doi: 10.1016/j.ijmyco.2016.10.015. Epub 2016 Oct 27.

OBJECTIVE/BACKGROUND: Pyrazinamide (PZA) is an antibacterial used in the first-line regimen against tuberculosis (TB) for its action against dormant bacilli. PZA is also included in the new short regimen to treat multidrug-resistant TB (MDR-TB). However, the prevalence and significance...

Cite
Daneau G, Gumusboga M, De Rijk P, et al. The majority of patients with multidrug-resistant tuberculosis in Sub-Saharan Africa present a concomitant resistance to pyrazinamide. Int J Mycobacteriol. 2016;5:S46-S47doi: 10.1016/j.ijmyco.2016.10.015.
Daneau, G., Gumusboga, M., De Rijk, P., Trebucq, A., Rigouts, L., Van Deun, A., & de Jong, B. C. (2016). The majority of patients with multidrug-resistant tuberculosis in Sub-Saharan Africa present a concomitant resistance to pyrazinamide. International journal of mycobacteriology, 5S46-S47. https://doi.org/10.1016/j.ijmyco.2016.10.015
Daneau, Géraldine, et al. "The majority of patients with multidrug-resistant tuberculosis in Sub-Saharan Africa present a concomitant resistance to pyrazinamide." International journal of mycobacteriology vol. 5 (2016): S46-S47. doi: https://doi.org/10.1016/j.ijmyco.2016.10.015
Daneau G, Gumusboga M, De Rijk P, Trebucq A, Rigouts L, Van Deun A, de Jong BC. The majority of patients with multidrug-resistant tuberculosis in Sub-Saharan Africa present a concomitant resistance to pyrazinamide. Int J Mycobacteriol. 2016 Dec;5:S46-S47. doi: 10.1016/j.ijmyco.2016.10.015. Epub 2016 Oct 27. PMID: 28043604.
Copy Download .nbib Format: NLM
Xpert MTB/RIF for rapid detection of rifampicin-resistant Mycobacterium tuberculosis from pulmonary tuberculosis patients in Southwest Ethiopia.

International journal of mycobacteriology

Tadesse M, Aragaw D, Dimah B, Efa F, Abebe G.
PMID: 28043605
Int J Mycobacteriol. 2016 Dec;5:S48-S49. doi: 10.1016/j.ijmyco.2016.09.002. Epub 2016 Nov 05.

OBJECTIVE/BACKGROUND: Accurate and rapid detection of drug-resistant strains of tuberculosis (TB) is critical for early initiation of treatment and for limiting the transmission of drug-resistant TB. Here, we investigated the accuracy of Xpert MTB/RIF for detection of rifampicin (RIF)...

Cite
Tadesse M, Aragaw D, Dimah B, et al. Xpert MTB/RIF for rapid detection of rifampicin-resistant Mycobacterium tuberculosis from pulmonary tuberculosis patients in Southwest Ethiopia. Int J Mycobacteriol. 2016;5:S48-S49doi: 10.1016/j.ijmyco.2016.09.002.
Tadesse, M., Aragaw, D., Dimah, B., Efa, F., & Abebe, G. (2016). Xpert MTB/RIF for rapid detection of rifampicin-resistant Mycobacterium tuberculosis from pulmonary tuberculosis patients in Southwest Ethiopia. International journal of mycobacteriology, 5S48-S49. https://doi.org/10.1016/j.ijmyco.2016.09.002
Tadesse, Mulualem, et al. "Xpert MTB/RIF for rapid detection of rifampicin-resistant Mycobacterium tuberculosis from pulmonary tuberculosis patients in Southwest Ethiopia." International journal of mycobacteriology vol. 5 (2016): S48-S49. doi: https://doi.org/10.1016/j.ijmyco.2016.09.002
Tadesse M, Aragaw D, Dimah B, Efa F, Abebe G. Xpert MTB/RIF for rapid detection of rifampicin-resistant Mycobacterium tuberculosis from pulmonary tuberculosis patients in Southwest Ethiopia. Int J Mycobacteriol. 2016 Dec;5:S48-S49. doi: 10.1016/j.ijmyco.2016.09.002. Epub 2016 Nov 05. PMID: 28043605.
Copy Download .nbib Format: NLM
Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons.

World journal of virology

Akolo C, Bada F, Okpokoro E, Nwanne O, Iziduh S, Usoroh E, Ali T, Ibeziako V, Oladimeji O, Odo M.
PMID: 25964875
World J Virol. 2015 May 12;4(2):105-12. doi: 10.5501/wjv.v4.i2.105.

Isoniazid preventive therapy (IPT) is the administration of isoniazid (INH) to people with latent tuberculosis (TB) infection (LTBI) to prevent progression to active TB disease. Despite being life-saving for human immunodeficiency virus (HIV)-infected persons who do not have active...

Cite
Akolo C, Bada F, Okpokoro E, et al. Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons. World J Virol. 2015;4(2):105-12doi: 10.5501/wjv.v4.i2.105.
Akolo, C., Bada, F., Okpokoro, E., Nwanne, O., Iziduh, S., Usoroh, E., Ali, T., Ibeziako, V., Oladimeji, O., & Odo, M. (2015). Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons. World journal of virology, 4(2), 105-12. https://doi.org/10.5501/wjv.v4.i2.105
Akolo, Christopher, et al. "Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons." World journal of virology vol. 4,2 (2015): 105-12. doi: https://doi.org/10.5501/wjv.v4.i2.105
Akolo C, Bada F, Okpokoro E, Nwanne O, Iziduh S, Usoroh E, Ali T, Ibeziako V, Oladimeji O, Odo M. Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons. World J Virol. 2015 May 12;4(2):105-12. doi: 10.5501/wjv.v4.i2.105. PMID: 25964875; PMCID: PMC4419114.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 1265 entries